Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04631718
Other study ID # 2020-0761
Secondary ID 1R01DK117354-01A
Status Completed
Phase
First received
Last updated
Start date January 18, 2022
Est. completion date April 29, 2024

Study information

Verified date May 2024
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The overall goal of this project is to develop and validate a novel technique for Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM) of the abdomen, for non-invasive assessment of liver iron deposition. In this work, study team will develop and optimize advanced data acquisition and image reconstruction methods to enable QSM of the abdomen. Further, investigators will determine the accuracy, repeatability, and reproducibility of abdominal QSM for iron quantification in patients with liver iron overload. Excessive accumulation of iron in various organs, including the liver, which affects both adult and pediatric populations, is toxic and requires treatment aimed at reducing body iron stores. Accurate assessment of liver iron concentration is critical for the detection and staging of iron overload as well as for longitudinal monitoring during treatment. In summary, this project will develop a novel MRI-based QSM technique designed for the abdomen and will validate it in pediatric and adult patients with liver iron overload. Upon successful validation, QSM will provide accurate, repeatable, and reproducible quantification of LIC based on a fundamental property of tissue.


Recruitment information / eligibility

Status Completed
Enrollment 63
Est. completion date April 29, 2024
Est. primary completion date April 29, 2024
Accepts healthy volunteers No
Gender All
Age group 5 Years and older
Eligibility Inclusion Criteria: - Ages 10 years or older at University of Wisconsin - Madison - Age 5 years or older at Stanford - Known or suspected iron overload Exclusion Criteria: - Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, etc) - Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening) - Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met: - The subject has their own prescription for the medication. - The informed consent process is conducted prior to the self-administration of this medication - They come to the research visit with a driver

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)
MRI-based QSM methods estimate the susceptibility of tissues based on measuring the magnetic field distortion produced by the tissues themselves. Upon successful validation, MRI-based abdominal QSM will provide accurate, repeatable, and reproducible quantification of Liver iron concentration (LIC) that is independent of the distribution of iron and does not require calibration.

Locations

Country Name City State
United States University of Wisconsin Madison Wisconsin
United States School of Medicine, Stanford University Stanford California

Sponsors (3)

Lead Sponsor Collaborator
University of Wisconsin, Madison National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Establishing the accuracy of MRI-QSM of the liver using SQUID-BLS as a reference Determine the accuracy of abdominal QSM to quantify liver iron concentration at 1.5T and 3T, in pediatric and adult patients with liver iron overload, using superconducting quantum interference device (SQUID)-based biomagnetic liver susceptometry (BLS) as the reference. 1.5 hours
Primary Establishing the repeatability of MRI-QSM of the liver Repeatability of MRI-QSM of the liver will be established in both pediatrics and adult participants. Each participant will be scanned at both 1.5T and 3T and at UW will repeat one of the field strengths to assess repeatability. Therefore, each participant at UW will undergo 3 MRI exams and each participant at Stanford 2 MRI exams.
Repeatability will not be tested at Stanford in order to avoid exhaustion of the patients (many of whom will be children), and to ensure the completion of acquisitions at both field strengths for validation of accuracy versus SQUID-BLS. Scanning will take 1.5 hour at University of Wisconsin and I hour at Stanford
up to 1.5 hours
Primary Establishing the reproducibility of MRI-QSM of the liver The reproducibility of abdominal MRI-based Quantitative Susceptibility Mapping (MRI-QSM) will be characterized across field strengths (1.5Tesla and 3Tesla), in both pediatric and adult participants with iron overload The repeated acquisitions at 1.5T and 3T will enable analysis of reproducibility of MRI-QSM across field strengths. At UW only, participants repeat either the 1.5T or 3T exam, with consideration given to the subject's schedule and magnet availability. Repeat tests will be performed after removing the participants from the magnet and repositioning with new localizer images. Repeatability will not be tested at Stanford in order to avoid exhaustion of the patients (many of whom will be children), and to ensure the completion of acquisitions at both field strengths for validation of accuracy versus SQUID-BLS.
Scanning will take 1.5 hour at University of Wisconsin and I hour at Stanford
up to 1.5 hours
Primary Optimizing MRI-based QSM performance by using multiple QSM reconstruction and measurement Multiple QSM reconstructions will be applied to each acquired dataset, to evaluate the effect of each reconstruction component on the performance of QSM.
Susceptibility measurements will be made by placing a region-of-interest in each of the nine Couinaud segments of the liver. This will allow segment-by-segment analysis as well as whole-liver analysis (by averaging over the 9 segments) of the performance of QSM. The reader performing MRI analysis will be blinded to SQUID results.
Scanning will take 1.5 hour at University of Wisconsin and I hour at Stanford.
up to 1.5 hours
Primary MRI-QSM data acquisition with Breath held An optimized acquisition will obtain 3D whole liver coverage within a ~20 second breath-hold. Data will be collected at 1.5T and 3T 1.5 hours
Primary MRI-QSM data acquisition with Free Breathing The optimized free-breathing acquisitions (using bellows, butterfly navigators, and 2D sequential acquisitions and requiring 3-5 min each) will be performed. Data will be collected at 1.5T and 3T 1.5 hours
Secondary Comparison of MRI-based QSM of the liver to serum ferritin measurements MRI-based QSM of the liver will be compared to serum ferritin measurements to validate MRI-QSM method. MRI-QSM visit will be scheduled within +/-2 days of serum ferritin measurement visit up to 3.5 hours
See also
  Status Clinical Trial Phase
Recruiting NCT04423237 - Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
Completed NCT04614779 - Long-term Clinical Study of CN128 in Thalassemia Patients Phase 2
Withdrawn NCT03800446 - Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood N/A
Not yet recruiting NCT02833493 - Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload N/A
Completed NCT02164253 - Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients Phase 2
Completed NCT00512226 - Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia N/A
Completed NCT00901199 - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload Phase 2
Recruiting NCT00378469 - Study of the Effects of Muscular Activity on Iron Metabolism N/A
Completed NCT00117507 - Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients Phase 4
Completed NCT00138684 - Cytochrome P450 2E1 and Iron Overload Phase 2
Completed NCT03990181 - Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement N/A
Terminated NCT02274233 - Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia Phase 1
Active, not recruiting NCT01443195 - Iron Metabolism in Small Pre Term Newborns N/A
Completed NCT01546415 - Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia Phase 4
Completed NCT01572818 - Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients N/A
Not yet recruiting NCT00980421 - Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children Phase 3
Completed NCT01047098 - Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation N/A
Recruiting NCT05294471 - Fully Automated High-Throughput Quantitative MRI of the Liver
Completed NCT03591575 - Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children Phase 4
Active, not recruiting NCT00907283 - Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA) Phase 2